Strategies to tackle RAS-mutated metastatic colorectal cancer.
KRAS
RAS
adagrasib
colorectal cancer
sotorasib
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
06
04
2021
revised:
22
04
2021
accepted:
23
04
2021
pubmed:
28
5
2021
medline:
30
10
2021
entrez:
27
5
2021
Statut:
ppublish
Résumé
The RAS oncogene is among the most commonly mutated in cancer. RAS mutations are identified in about half of patients diagnosed with metastatic colorectal cancer (mCRC), conferring poor prognosis and lack of response to anti-epidermal growth factor receptor (EGFR) antibodies. In the last decades, several investigational attempts failed in directly targeting RAS mutations, thus RAS was historically regarded as 'undruggable'. Recently, novel specific KRAS
Identifiants
pubmed: 34044286
pii: S2059-7029(21)00116-2
doi: 10.1016/j.esmoop.2021.100156
pmc: PMC8167159
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
100156Informations de copyright
Copyright © 2021. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Disclosure SS is an advisory board member for Amgen, Bayer, Bristol-Myers Squibb, CheckmAb, Clovis, Daiichi-Sankyo, Merck, Roche-Genentech, and Seattle Genetics. ASB is an advisory board member for Amgen, Bayer, Sanofi, and Servier. FS reports grants from Pfizer, lecture fees from Novartis and Merck Sharp & Dohme, and has served on advisory board for GlaxoSmithKline, outside the submitted work. The other authors declare no conflicts of interest.
Références
Cancers (Basel). 2019 Dec 13;11(12):
pubmed: 31847096
Cancer Res. 2007 Mar 15;67(6):2643-8
pubmed: 17363584
Cancer Chemother Pharmacol. 2020 May;85(5):917-930
pubmed: 32274564
ACS Omega. 2019 Feb 28;4(2):2921-2930
pubmed: 30842983
Oncogene. 2019 Jun;38(25):5076-5090
pubmed: 30905967
Clin Colorectal Cancer. 2016 Sep;15(3):222-7
pubmed: 26975418
J Clin Oncol. 2013 Feb 20;31(6):759-65
pubmed: 23182985
PLoS One. 2014 Nov 06;9(11):e112201
pubmed: 25375154
Clin Cancer Res. 2019 Oct 15;25(20):6243-6259
pubmed: 31375513
Invest New Drugs. 2016 Dec;34(6):740-749
pubmed: 27450049
Mol Cell Proteomics. 2016 Sep;15(9):2924-38
pubmed: 27340238
Front Oncol. 2020 Apr 28;10:570
pubmed: 32457830
Clin Cancer Res. 2015 Feb 15;21(4):739-48
pubmed: 25516890
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20723-8
pubmed: 24297898
Clin Cancer Res. 2020 Mar 15;26(6):1372-1384
pubmed: 31831554
Clin Cancer Res. 2014 Aug 15;20(16):4193-9
pubmed: 24907112
J Clin Oncol. 2010 Mar 1;28(7):1254-61
pubmed: 20100961
Mol Cancer Res. 2015 Sep;13(9):1325-35
pubmed: 26037647
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
N Engl J Med. 2020 Sep 24;383(13):1207-1217
pubmed: 32955176
Nature. 2017 Dec 7;552(7683):116-120
pubmed: 29186113
Target Oncol. 2017 Dec;12(6):775-785
pubmed: 29067643
Eur J Cancer. 2017 Jul;79:50-60
pubmed: 28463756
BMC Cancer. 2019 May 16;19(1):460
pubmed: 31096937
Lancet Oncol. 2012 Aug;13(8):773-81
pubmed: 22805291
Cancer Chemother Pharmacol. 2015 Jan;75(1):183-9
pubmed: 25417902
Curr Opin Chem Biol. 2016 Feb;30:61-67
pubmed: 26629855
Acta Oncol. 2013 Jun;52(5):963-70
pubmed: 23514584
Oncogene. 2010 Aug 12;29(32):4576-87
pubmed: 20531295
Gastroenterology. 2020 Mar;158(4):806-811
pubmed: 31972237
Clin Cancer Res. 2013 Apr 15;19(8):2265-72
pubmed: 23422094
Nature. 2012 Jan 26;483(7387):100-3
pubmed: 22281684
Cancers (Basel). 2019 Mar 30;11(4):
pubmed: 30935038
Clin Cancer Res. 2016 Jan 15;22(2):405-14
pubmed: 26369631
Sci Rep. 2020 Dec 10;10(1):21671
pubmed: 33303890
Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5299-304
pubmed: 22431598
Cancer Discov. 2014 Jan;4(1):19-21
pubmed: 24402942
Oncologist. 2020 Jan;25(1):e160-e169
pubmed: 31395751
Nat Med. 2015 Jul;21(7):827
pubmed: 26151329
Cancer Cell. 2013 Jan 14;23(1):121-8
pubmed: 23245996
Eur J Cancer. 2014 Dec;50(18):3136-44
pubmed: 25441408
BMC Cancer. 2016 May 31;16:339
pubmed: 27246726
Nat Commun. 2019 Aug 19;10(1):3722
pubmed: 31427573
Oncologist. 2017 Sep;22(9):1024-e89
pubmed: 28592615
Science. 2015 Dec 11;350(6266):1391-6
pubmed: 26541605
Adv Ther. 2019 Jun;36(6):1480-1484
pubmed: 30980281
Oncotarget. 2016 Jul 26;7(30):47954-47965
pubmed: 27323830
Target Oncol. 2020 Apr;15(2):163-174
pubmed: 32314268
Blood. 2018 Jan 4;131(1):49-57
pubmed: 29118009
Nature. 2019 Nov;575(7781):217-223
pubmed: 31666701
J Clin Oncol. 2004 Oct 1;22(19):3950-7
pubmed: 15459217
Clin Cancer Res. 2014 Mar 15;20(6):1656-65
pubmed: 24493827
Cell. 1998 May 15;93(4):605-15
pubmed: 9604935
Invest New Drugs. 2015 Dec;33(6):1242-7
pubmed: 26386973
Anticancer Drugs. 2015 Sep;26(8):872-7
pubmed: 26053280
NAR Cancer. 2020 Feb 17;2(1):zcaa002
pubmed: 34316682
Invest New Drugs. 2016 Oct;34(5):604-13
pubmed: 27424159
Cancer Discov. 2020 Jan;10(1):54-71
pubmed: 31658955
Angew Chem Int Ed Engl. 2012 Jun 18;51(25):6140-3
pubmed: 22566140
Cancers (Basel). 2021 Jan 04;13(1):
pubmed: 33406649
Mol Cancer Ther. 2018 Jan;17(1):3-16
pubmed: 29295962
Nat Cancer. 2020 Jan;1(1):25-27
pubmed: 35121842
Clin Cancer Res. 2012 May 1;18(9):2515-25
pubmed: 22392911
Cancer Chemother Pharmacol. 2015 Jan;75(1):17-23
pubmed: 25322874
Sci Transl Med. 2017 Jun 14;9(394):
pubmed: 28615361
Clin Cancer Res. 2015 Feb 15;21(4):730-8
pubmed: 25500057
Oncotarget. 2016 Jun 28;7(26):39595-39608
pubmed: 27167191
Cancer Res. 2012 May 15;72(10):2457-67
pubmed: 22589270
Cancer Discov. 2020 Aug;10(8):1129-1139
pubmed: 32430388
Nature. 2012 Jun 28;486(7404):532-6
pubmed: 22722830
Br J Cancer. 2018 Dec;119(12):1471-1476
pubmed: 30425349
Ann Oncol. 2013 Jul;24(7):1777-1785
pubmed: 23510984
Nat Rev Clin Oncol. 2018 Nov;15(11):709-720
pubmed: 30275515
Invest New Drugs. 2015 Jun;33(3):720-8
pubmed: 25637165
Oncogene. 2017 Nov 23;36(47):6581-6591
pubmed: 28783173
Cell. 2017 Jun 29;170(1):17-33
pubmed: 28666118
Biochem Soc Trans. 2020 Jun 30;48(3):1101-1108
pubmed: 32379297
Cancer Res. 2018 Sep 15;78(18):5398-5407
pubmed: 30042150
J Transl Med. 2014 Feb 24;12:55
pubmed: 24565030
Ann Oncol. 2015 Dec;26(12):2503
pubmed: 26371285
J Clin Oncol. 2005 Apr 10;23(11):2521-33
pubmed: 15710949
Invest New Drugs. 2020 Apr;38(2):419-432
pubmed: 31020608
Invest New Drugs. 2016 Apr;34(2):168-75
pubmed: 26666244
Nat Rev Drug Discov. 2020 Aug;19(8):533-552
pubmed: 32528145
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
J Clin Oncol. 2008 Jan 20;26(3):374-9
pubmed: 18202412
Ann Oncol. 2002 Jul;13(7):1067-71
pubmed: 12176785
Nature. 2013 Nov 28;503(7477):548-51
pubmed: 24256730
Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4300-4305
pubmed: 28400509
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Pathol Oncol Res. 2020 Jul;26(3):1957-1969
pubmed: 31902117
Invest New Drugs. 2014 Jun;32(3):535-41
pubmed: 24468885
Cell Rep. 2019 Jan 2;26(1):65-78.e5
pubmed: 30605687
Cancer Chemother Pharmacol. 2013 Jul;72(1):139-46
pubmed: 23670640
Ann Oncol. 2020 Sep;31(9):1135-1147
pubmed: 32512040
PLoS One. 2013 Nov 11;8(11):e62264
pubmed: 24244261
Br J Cancer. 2015 Jun 9;112(12):1874-81
pubmed: 25989270
Cell Cycle. 2017;16(22):2176-2182
pubmed: 28296564
J Natl Cancer Inst. 2016 Dec 31;109(5):
pubmed: 28040692
Mol Cancer Ther. 2021 Jun;20(6):975-985
pubmed: 33722854
Lancet Oncol. 2019 Jun;20(6):849-861
pubmed: 31003911
N Engl J Med. 2013 Sep 12;369(11):1023-34
pubmed: 24024839
Innovation (Camb). 2020 Aug 28;1(2):
pubmed: 32939510
World J Gastrointest Oncol. 2018 Oct 15;10(10):290-292
pubmed: 30364839